Trailing Twelve Months Revenue Growth: Lixte Biotechnology, Inc. (LIXT)

Public company logo of lixte.com (LIXT)

Lixte Biotechnology is developing a network for creating LB-100 inhibitors through strategic alliances with scientific centers, while the success of its cancer therapy relies on medical efficacy rather than market cycles. This rolling annual sales growth chart reflects revenue dynamics, where the indicator value stands at 0.00. The company is currently funding early-stage tests using its existing cash reserves.

Lixte Biotechnology (LIXT): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 07/06/2026

Lixte Biotechnology - analytical breakdowns and key metrics (LIXT)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Lixte Biotechnology Holdings
Brand item of Lixte Biotechnology, Inc.

Capital must distinguish fundamental growth from short-term speculation. The Lixte Biotechnology (LIXT) model, which outsources testing to external CRO partners, minimizes costs while maintaining control over patents. By analyzing the LTM sales growth YoY, an investor can see the percentage increase in revenue over a trailing twelve-month period. Daily data tracking on this chart allows for the immediate identification of abnormal spikes or trend reversals, confirming the actual resilience of the business's revenue.

Who Lixte Biotechnology competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) citiuspharma.com|CLRB: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BLRX|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)